Physician profile
James E Dowd
NPI 1104855667
$6,075,511.73
in general payments reported to CMS, 2019-2025
13 companies · $747K in 2025
The $747K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946K · 2020: $734K · 2021: $894K · 2022: $845K · 2023: $1.2M · 2024: $719K · 2025: $747K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $2.2M · Acquisitions: $347K · Consulting Fee: $118K · Travel and Lodging: $8,268 · Food and Beverage: $3,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $2,180,163.46 |
| Acquisitions | $347,055.72 |
| Consulting Fee | $117,761.25 |
| Travel and Lodging | $8,267.60 |
| Food and Beverage | $3,984.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Products, INC. | $4,784,522.46 | 2019-2025 | Attune, S-Rom Noiles, Lps |
| Zimmer Biomet Holdings, INC. | $933,238.61 | 2019-2025 | Tapestry, Echo |
| Medical Device Business Services, INC. | $285,463.02 | 2019-2025 | Attune, S-Rom Noiles, Lps |
| Medacta USA, INC. | $63,273.17 | 2020-2025 | Quadra, Amistem, Mfinity Cup |
| Kyocera Medical Technologies, INC. | $5,184.12 | 2024-2025 | |
| Depuy Synthes Sales INC. | $3,414.18 | 2019-2025 | Attune, Lps, S-Rom Noiles |
| Ethicon US, LLC | $126.64 | 2024 | Stratafix, Ethicon, Dermabond Prineo |
| Exactech, INC. | $114.58 | 2019 | |
| Karl Storz Endoscopy-America | $76.39 | 2019 | |
| Stryker Corporation | $34.34 | 2019-2023 | Restoration |
| Fidia Pharma USA INC. | $33.27 | 2022-2023 | Hymovis |
| Collegium Pharmaceutical, INC. | $18.60 | 2025 | Jornay Pm |
| Bioventus LLC | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,186,383.36 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dowd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.